Perturbations of miRNAs in Igf2-p and H19-m mutants used in study
H19-m vs. wild-type: significantly downregulatedmiRNAs
Gene / Fold change / Adjusted P value / Functionmmu-miR-675-3p / 0.78 / < 0.001 / Upregulated in CRC, targets RB for degradation(Tsang et al., 2010)
mmu-miR-219† / 0.81 / < 0.001 / Not known
mmu-miR-376a / 0.83 / < 0.001 / Upregulated in pancreatic cancer(Lee et al., 2007), overexpression confers tumourigenicity (Teferedegne et al., 2010)
mmu-miR-141 / 0.87 / 0.002 / Upregulated in CRC (Cheng et al., 2011)
mmu-miR-142-3p / 0.88 / 0.002 / Suppresses migration and invasion through downregulation of RAC1 (Wu et al., 2011)
mmu-miR-130a / 0.89 / 0.004 / Suppresses tumouregenicity via downregulation of MET (Acunzo et al., 2011)
mmu-miR-381 / 0.89 / 0.008 / Oncogenic in GBM (Tang et al., 2011)
mmu-miR-124 / 0.89 / 0.035 / Putative tumour suppressor (Zheng et al., 2011)
mmu-miR-33† / 0.9 / < 0.001 / Not known
mmu-let-7a† / 0.9 / < 0.001 / Expression decreased in malignancy(Muller and Bosserhoff, 2008; Yanaihara et al., 2006)
H19-m vs. wild-type: Significantly upregulated miRNAs
Gene / Fold change / Adjusted P value / Functionmmu-miR-134 / 1.11 / 0.035 / Not known
mmu-miR-409-3p / 1.09 / 0.006 / Not known
mmu-miR-101b:9.1 / 1.08 / 0.018 / Not known
mmu-miR-99b / 1.08 / 0.035 / Putative oncogenic role in synovial sarcoma (Hisaoka et al., 2011)
mmu-miR-674 / 1.06 / 0.004 / Not known
mmu-miR-302d / 1.06 / 0.015 / Not known
mmu-miR-382 / 1.06 / 0.047 / Not known
mmu-miR-431 / 1.05 / 0.002 / Not known
mmu-miR-127 / 1.05 / 0.013 / Not known
mmu-miR-324-5p / 1.05 / 0.018 / Downregulated in medulloblastoma (Ferretti et al., 2008)
Igf2-p vs. wild-type: significantly downregulated miRNAs
Gene / Fold change / Adjusted P value / Functionmmu-miR-219† / 0.85 / < 0.001 / Not known
mmu-miR-144:9.1 / 0.9 / 0.022 / NK
mmu-miR-125a-5p / 0.9 / 0.038 / Putative tumour suppressor (Nishida et al., 2011)
mmu-miR-10a / 0.91 / 0.038 / Upregulated in pancreatic cancer (Weiss et al., 2009)
mmu-let-7a† / 0.91 / 0.038 / Expression decreased in malignancy (Muller and Bosserhoff, 2008; Yanaihara et al., 2006)s
mmu-miR-33† / 0.92 / < 0.001 / Not known
mmu-miR-30c / 0.95 / 0.038 / Expression correlates with response to endocrine therapy in breast cancer (Rodriguez-Gonzalez et al., 2011)
mmu-miR-301b / 0.96 / 0.022 / Upregulated in CRC (Wang et al., 2010)
mmu-miR-689 / 0.99 / 0.038 / Not known
Igf2-p vs. wild-type: significantly upregulated miRNAs
Gene / Fold change / Adjusted P value / Functionmmu-miR-293 / 1.14 / 0.022 / ES differentiation (Ciaudo et al., 2009)
mmu-miR-133a / 1.12 / 0.038 / Tumour suppressor (Yoshino et al., 2011)
mmu-miR-483* / 1.07 / < 0.001 / Upregulated in malignancy, anti-apoptotic (Veronese et al., 2010)
mmu-miR-340-3p / 1.07 / 0.038 / Not known
mmu-miR-154 / 1.06 / 0.038 / Not known
mmu-miR-323-3p / 1.06 / 0.038 / Not known
mmu-miR-434-3p / 1.06 / 0.038 / Not known
mmu-miR-338-3p / 1.06 / 0.047 / Lost in hepatocellular carcinoma (Huang et al., 2011)
mmu-miR-487b / 1.05 / 0.038 / Not known
Supplementary references
Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D et al (2011). miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene.
Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M et al (2011). Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One6: e17745.
Ciaudo C, Servant N, Cognat V, Sarazin A, Kieffer E, Viville S et al (2009). Highly dynamic and sex-specific expression of microRNAs during early ES cell differentiation. PLoS Genet5: e1000620.
Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M et al (2008). Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J27: 2616-27.
Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H et al (2011). Identification of altered MicroRNA expression patterns in synovial sarcoma. Genes Chromosomes Cancer50: 137-45.
Huang XH, Chen JS, Wang Q, Chen XL, Wen L, Chen LZ et al (2011). miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol.
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL et al (2007). Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer120: 1046-54.
Muller DW, Bosserhoff AK (2008). Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene27: 6698-706.
Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F et al (2011). MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res17: 2725-33.
Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V et al (2011). MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat127: 43-51.
Tang H, Liu X, Wang Z, She X, Zeng X, Deng M et al (2011). Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res1390: 21-32.
Teferedegne B, Murata H, Quinones M, Peden K, Lewis AMC (2010). Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro. PLoS One5: e14416.
Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ et al (2010). Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis31: 350-8.
Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F et al (2010). Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res70: 3140-9.
Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ (2010). Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis11: 50-4.
Weiss FU, Marques IJ, Woltering JM, Vlecken DH, Aghdassi A, Partecke LI et al (2009). Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology137: 2136-45 e1-7.
Wu L, Cai C, Wang X, Liu M, Li X, Tang H (2011). MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett585: 1322-30.
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell9: 189-98.
Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K et al (2011). The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer104: 808-18.
Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP et al (2011). The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut.